GSH-Responsive Silica Nanoparticles for Biomolecule Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral nanovectors for delivering biomacromolecules, such as nucleic acids and CRISPR ribonucleoproteins, face challenges including low payload encapsulation efficiency, high cytotoxicity, and insufficient in vivo stability, as well as difficulties in cellular uptake and endosomal escape.
Innovation Solution
Development of multi-functional GSH-responsive silica nanoparticles (SNPs) with disulfide crosslinks and surface-modifying groups like PEG, polysarcosine, and polyzwitterion, which facilitate efficient delivery of biomolecules by maintaining payload activity, enabling rapid release and endosomal escape while ensuring biocompatibility and small particle size.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-viral nanovectors are used for delivering biomacromolecules, then cytotoxicity is reduced compared to viral vectors, but payload encapsulation efficiency and in vivo stability become insufficient
Solution Approach 1:
The patent employs a composite nanoparticle structure combining a silica core with polymeric functional groups (including cationic polymers for nucleic acid binding and PEG for steric stabilization). This composite architecture enables simultaneous achievement of high payload encapsulation efficiency through electrostatic interactions and low cytotoxicity through biocompatible surface modification, resolving the contradiction between safety and delivery effectiveness.
Solution Approach 2:
The patent utilizes pH-responsive parameter changes to achieve endosomal escape. The nanoparticle structure undergoes conformational changes in response to endosomal pH, transitioning from a stable configuration at physiological pH to a disrupted configuration at acidic endosomal pH, enabling payload release. This parameter-based response mechanism improves in vivo stability while maintaining delivery effectiveness.
2Productivity
If nanoparticle size is reduced to improve cellular uptake, then delivery efficiency increases, but payload capacity decreases
Solution Approach 1:
The patent applies local quality differentiation within the nanoparticle structure, with the internal silica core providing high-density payload binding sites for maximum encapsulation capacity, while the external polymeric surface provides hydrodynamic properties optimized for cellular uptake. This spatial differentiation of functional properties enables small particle size (10-100 nm) to coexist with high payload capacity through efficient use of internal volume.
3Productivity
If nucleic acids are delivered naked to achieve rapid protein production, then transfection efficiency is high, but enzymatic degradation occurs under physiological conditions
Solution Approach 1:
The patent introduces a polymeric intermediary layer between the nucleic acid payload and the physiological environment. This polymeric coating acts as a protective mediator that shields nucleic acids from enzymatic degradation while allowing cellular uptake mechanisms to function. The intermediary structure enables naked-like transfection efficiency while providing the protective function normally associated with complex formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SNPs achieve high loading content and efficiency, efficient endosomal escape, and biocompatibility, effectively delivering biomolecules into cells with minimal cytotoxicity and improved therapeutic potential.
Implementation Method 1
GSH-responsive silica nanoparticles
Implementation Method 2
surface-modifying groups comprise polyethylene glycol (PEG)
Implementation Method 3
polysarcosine, polyzwitterion or combinations of two or more thereof
Data Source
AI summary
The present technology provides a nanoparticle comprising: the polysiloxanes comprise silyloxy subunits having the structure (I) as shown herein, wherein Ra at each occurrence is independently selected from a bond to a Si of another polysiloxane chain or a C1-12 alkyl group; Ri at each occurrence is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl groups, optionally substituted with a substituent selected from the group consisting of halogen and NR12, wherein each occurrence of R1 is independently selected from H or a C1-12 alkyl group, or two R1 groups, together with the N atom to which they are attached, form a pyrrolidine or piperidine ring; the crosslinks between polysiloxanes comprise disulfide linkages, the nanoparticle comprises an exterior surface comprising surface-modifying groups attached to and surrounding the silica network, wherein the surface-modifying groups comprise polyethylene glycol (PEG), polysarcosine, polyzwitterion, polycation, polyanion, or combinations of two or more thereof; and the nanoparticle has an average diameter of 15 nm to 200 nm. The nanoparticles herein may include biomolecules such as polynucleic acids, proteins, and complexes thereof, e.g., Cas9 RNP.